Skip to main content
. 2021 Jul 13;22(14):7501. doi: 10.3390/ijms22147501

Figure 2.

Figure 2

NPD-0614-13 and NPD-0614-24 safety profile in different skin cell populations. (a) Western blot and corresponding densitometric analysis of K7 and K10 protein expression in SZ95 sebocytes treated with NPD-0614-13 (25 μM), NPD-0614-24 (25 μM) and FICZ (100 nM) for 48 h. (b) Percentage composition of saturated, mono- and polyunsaturated fatty acids in SZ95 sebocytes treated as above for 72 h. (c) Western blot and corresponding densitometric analysis of p53 and phospho-EGFR protein expression in NHKs treated as above for 48 h and 5 min, respectively. (d) Western blot and corresponding densitometric analysis of filaggrin and involucrin protein expression in NHKs treated as above for 48 h. (e) Phase-contrast analysis, western blot with corresponding densitometric analysis of tyrosinase protein expression and melanin content analysis in NHMs treated with NPD-0614-13 (25 μM), NPD-0614-24 (25 μM) and FICZ (100 nM) for 72 h and 5 days, respectively. GAPDH was used as an endogenous loading control for western blot analysis. Results are expressed as the fold change respect to untreated control cells. Data represent the mean ± SD of three independent experiments.